Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ctDNA.
- Who it may be relevant to
- Registry conditions: Resectable Pancreatic Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Implementing Non-invasive Circulating Tumor DNA and Circular DNA Analysis in Patients With Localized Pancreatic Cancer to Optimize the Pre- and Postoperative Treatment: Predicting Recurrence and Survival and Changing Prognosis Over Time
Overview
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall survival, and to investigate if plasma ctDNA combined with CT scan and endoscopic ultrasound surveillance increases the median overall survival compared with standard-of-care surveillance.
Detailed description
The aim of the CIRCPAC study is to evaluate if plasma ctDNA from patients scheduled for surgical resection of PDAC can identify patients who will benefit from surgery and if plasma ctDNA can identify recurrence earlier and improve the survival and quality of life of the patients compared with standard-of-care surveillance.
Patients operated for PDAC will be included in this Danish multicenter study including an observational study (Sub-study 1: 700 patients) and an interventional randomized trial (Sub-study 2: 410 patients).
In Sub-study 1, patients will have blood samples drawn prior to surgery, 4 weeks after surgery, and 6 months after surgery.
In Sub-study 2, patients without recurrence 4 months after surgery, will be randomized in a 1:1 manor to an experimental arm (arm A) with ctDNA guided surveillance, or to a control arm (B) with standard surveillance.
Interventions
- Diagnostic test ctDNA
ctDNA guided surveillance
Primary outcome measures
- Sub-study 1 ctDNA [Time frame: 36 months]
- Sub-study 1 eccDNA [Time frame: 36 months]
- Sub-study 2 ctDNA DFS [Time frame: 3 years from surgery for PDAC]
- Sub-study 2 ctDNA OS [Time frame: 3 years from surgery for PDAC]
- Sub-study 2 eccDNA [Time frame: 3 years from surgery for PDAC]
Eligibility criteria
Inclusion criteria
- Sub-study 1: Suspicion of PDAC tumor stage I-III, scheduled for pancreatic resection, with or without preoperative neoadjuvant chemotherapy.
- Sub-study 2: .
- PDAC tumor stage I-III
- Has received intended curative resection (R0/R1) of PDAC
- No signs of local recurrence or metastatic disease at a CT scan 4 months after the operation
Exclusion criteria
- Other cancers (excluding skin cancer other than melanoma) later than 3 years before inclusion
- Patients who are unlikely to comply with the protocol, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
Denmark · 5 centers
- Aalborg Universitetshospital — Aalborg
- Aarhus Universitetshospital — Aarhus
- Copenhagen University Hospital - Rigshospitalet — Copenhagen
- Copenhagen University Hospital - Herlev and Gentofte — Herlev
- Odense Universitetshospital — Odense
Identifiers
NCT: NCT05788744 · CIRCPAC